OCT Guidance Superior to Angiography for PCI in Complex Coronary Lesions: OCCUPI trial

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-09-06 22:45 GMT   |   Update On 2024-09-06 22:45 GMT

South Korea: A recent study from South Korea has demonstrated that optical coherence tomography (OCT) guidance significantly improves outcomes for patients undergoing percutaneous coronary interventions (PCI) with complex lesions compared to traditional angiography guidance. The trial, known as OCCUPI (Optical Coherence Tomography-guided versus Angiography-guided PCI for Patients with Complex Lesions), highlights a potential shift in how PCI procedures are approached.

Advertisement

In the OCCUPI trial, patients receiving PCI for complex coronary lesions with drug-eluting stents showed a notable decrease in major adverse cardiac events when guided by optical coherence tomography compared to standard angiography.

"The OCT-guided group experienced a 38% reduction in major adverse events, including cardiac death, myocardial infarction, stent thrombosis, or ischemia-driven target-vessel revascularization, at one year (5% versus 7%; HR 0.62)," the researchers reported in The Lancet.

Although OCT offers detailed imaging during percutaneous coronary intervention, the clinical advantages of this technique in such procedures are still not fully established. To fill this knowledge gap, Prof Sung-Jin Hong, Yonsei University College of Medicine, Seoul, South Korea, and colleagues aimed to compare the clinical benefits of OCT-guided versus angiography-guided PCI for complex lesions, evaluated as the rate of major adverse cardiac events (MACEs) at one year.

For this purpose, the researchers conducted an investigator-initiated, multicenter, randomized, open-label, superiority trial across 20 hospitals in South Korea, enrolling patients aged 19 to 85 who required PCI with drug-eluting stents. Following diagnostic angiography, patients were evaluated to determine if they had one or more complex lesions. Those meeting the criteria were then randomly assigned in a 1:1 ratio to either the OCT-guidance group, receiving PCI with OCT guidance, or the angiography-guidance group, which used traditional angiography without OCT.

PCI procedures followed conventional methods with everolimus-eluting stents. The study's primary endpoint was the incidence of MACE, a composite measure including cardiac death, myocardial infarction, stent thrombosis, and ischemia-driven target-vessel revascularization, assessed one year after PCI. The primary analysis was conducted on an intention-to-treat basis, with a margin of 1.0 used to establish superiority.

The following were the key findings of the study:

  • Between Jan 9, 2019, and Sept 22, 2022, 1604 patients requiring PCI with drug-eluting stents for complex lesions were randomly assigned to receive either OCT-guided PCI (n=803) or angiography-guided PCI (n=801).
  • 80% of 1604 patients were male and 20% were female. The median age of patients at randomisation was 64 years. 99% of patients completed 1-year follow-up.
  • The primary endpoint occurred in 5% of 803 patients in the OCT-guided PCI group and 7% of 801 patients in the angiography-guided PCI group (absolute difference –2·8%; hazard ratio 0·62).
  • Rates of stroke, bleeding events, and contrast-induced nephropathy were not significantly different across the two groups.

The study revealed that in patients needing drug-eluting stent implantation for complex lesions, OCT guidance led to a lower rate of major adverse cardiac events at one year compared to traditional angiography guidance.

"These results suggest a therapeutic advantage of using OCT as an intravascular imaging technique for guiding PCI in individuals with complex coronary lesions," the researchers concluded.

Reference:

Hong SJ, Lee SJ, Lee SH, et al., for the OCCUPI Investigators. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicenter, randomized, open-label, superiority trial in South Korea. Lancet 2024;Sep 2:[Epub ahead of print].


Tags:    
Article Source : The Lancet

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News